Phase III Results Show Moderna Could Challenge In Blockbuster RSV Vaccine Market

First Data Cut Shows 83% Efficacy Against Infection

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.